Wide Ranks

ANIK

Anika Therapeutics Inc.

17.72

Top Statistics
Market Cap 259 M Forward PE 37.70 Revenue Growth -6.50 %
Current Ratio 5.34 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -59.40 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -27.90 Enterprise / Revenue 1.37 Price To Sales Trailing12 Months 1.58
Profitability
Profit Margins -59.40 % Operating Margins -64.29 %
Balance Sheet
Total Cash 62 M Total Cash Per Share 4.26 Total Debt 27 M
Total Debt To Equity 15.31 Current Ratio 5.34 Book Value Per Share 12.24
All Measures
Short Ratio 416.00 % Message Board Id finmb_328641 Fax 781 305 9720
Shares Short Prior Month 489054 Return On Equity -0.4331 City Bedford
Uuid ef258dda-d89e-3407-b824-c5d0079911f4 Previous Close 17.72 First Trade Date Epoch Utc 736 M
Book Value 12.24 Beta 0.8570 Total Debt 27 M
Volume 43655 Price To Book 1.45 Fifty Two Week Low 16.00
Total Cash Per Share 4.26 Total Revenue 164 M Shares Short Previous Month Date 1 B
Target Median Price 26.50 Audit Risk 9 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -64.29 % Target Mean Price 26.50
Net Income To Common -97520000 Short Percent Of Float 0.0483 Implied Shares Outstanding 14 M
Trailing Peg Ratio 191.33 % Last Fiscal Year End 1 B Average Daily Volume10 Day 126520
Average Volume10days 126520 Total Cash 62 M Next Fiscal Year End 1 B
Revenue Per Share 11.14 Held Percent Insiders 0.0342 Ebitda Margins -4.91 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 5 Regular Market Previous Close 17.72 Target Low Price 25.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 21.77 Open 17.84
Free Cashflow 14 M State MA Dividend Yield 0.00 %
Return On Assets -0.0401 Time Zone Short Name EST Board Risk 2
Trailing Eps -6.64 Day Low 17.65 Address1 32 Wiggins Avenue
Shares Outstanding 14 M Compensation Risk 4 Price Hint 2
Target High Price 28.00 Website https://www.anika.com 52 Week Change -0.1912
Average Volume 87545 Forward Eps -0.2000 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 355.90 % Is_sp_500 False
Regular Market Day High 17.90 Profit Margins -59.40 % Debt To Equity 15.31
Fifty Two Week High 29.12 Day High 17.90 Shares Short 508846
Regular Market Open 17.84 Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 %
Enterprise To Revenue 1.37 Revenue Growth -6.50 % Shares Percent Shares Out 0.0347
Operating Cashflow 7 M Currency USD Time Zone Full Name America/New_York
Market Cap 259 M Is_nasdaq_100 False Zip 01730
Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic Long Name Anika Therapeutics, Inc.
Overall Risk 4 Regular Market Day Low 17.65 Held Percent Institutions 0.9152
Current Price 17.72 Enterprise To Ebitda -27.90 Financial Currency USD
Current Ratio 5.34 Gross Margins 48.87 % Industry Disp Drug Manufacturers - Specialty & Generic
Number Of Analyst Opinions 2 Country United States Float Shares 10 M
Two Hundred Day Average 24.81 Governance Epoch Date 1 B Enterprise Value 224 M
Price To Sales Trailing12 Months 1.58 Forward PE 37.70 Regular Market Volume 43655
Ebitda -8054000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.

The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform.

Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief.

The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions.

In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products.

The company was founded in 1983 and is headquartered in Bedford, Massachusetts.